WHI-P131

CAS No. 202475-60-3

WHI-P131( Janex 1 )

Catalog No. M13153 CAS No. 202475-60-3

Janex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 50 In Stock
2MG 29 In Stock
5MG 46 In Stock
10MG 77 In Stock
25MG 130 In Stock
50MG 184 In Stock
100MG 276 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WHI-P131
  • Note
    Research use only, not for human use.
  • Brief Description
    Janex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3.
  • Description
    Janex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (IC50 = 78μM); has no effect on JAK1, JAK2, or Zap/Syk or SRC tyrosine kinases.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Janex 1
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK3| JAK3
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    202475-60-3
  • Formula Weight
    297.31
  • Molecular Formula
    C16H15N3O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    OC1=CC=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1
  • Chemical Name
    4-[(6,7-dimethoxy-4-quinazolinyl)amino]-phenol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sudbeck EA, et al. Clin Y Res. 1999 Jun;5(6): 1569-82.
molnova catalog
related products
  • Oclacitinib

    Oclacitinib(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM.

  • WHI-P97

    A potent, specific JAK3 inhibitor with Ki of 0.6-2.3 uM.

  • Lorpucitinib

    Lorpucitinib (JNJ-64251330) is an orally available, selective and potent JAK kinase inhibitor for the study of inflammatory and gastrointestinal disorders associated with Janus kinase (JAK) signaling.